A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Aerosolized Novaferon in Asymptomatic and Mildly Symptomatic Patients Infected With SARS-CoV-2.
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Novaferon (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; COVID-19 respiratory infection
- Focus Therapeutic Use
- 26 Aug 2021 New trial record